Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-escalation study of ONO-7475 alone and with nivolumab in advanced solid tumors
jRCT2080224028Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ONO-7475 and nivolumab in Nonhematologic neoplasms (2 arms), sponsored by Ono Pharmaceutical. Started Aug 2018; status: completed.
02
Drugs
ONO-7475nivolumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080224028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224028.